Managing the highly sensitized transplant recipient and B cell tolerance

Current Opinion in Immunology

Volumn 13, Issue 5, 2001, Pages 577-581

  Baid, Seema ^a   Saidman, Susan L ^a   Tolkoff Rubin, Nina ^a   Williams, Winfred W ^a   Delmonico, Francis L ^a   Cosimi, A Benedict ^a   Pascual, Manuel ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ANTIBODY; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACCIDENT PREVENTION; ANTIBODY PRODUCTION; B LYMPHOCYTE; CHIMERA; DRUG IDENTIFICATION; GRAFT REJECTION; HEMATOPOIESIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; REVIEW; SENSITIZATION; SERUM; SYNDROME; TIME;

ANIMALS; B-LYMPHOCYTES; HLA ANTIGENS; HUMANS; IMMUNIZATION; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; TRANSPLANTATION TOLERANCE;

EID: 0035479820     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00262-4     Document Type: Review

References (47)

1. Laboratory and clinical management of the highly sensitized organ transplant recipient
2. Sensitization in renal transplantation
3. The effect of panel reactive antibodies and donor specific crossmatches on graft survival after heart and heart-lung transplantation
4. Cardiac and lung transplantation
5. Cross-matching in liver transplantation
6. The lymphocytotoxic crossmatch test in clinical renal transplantation
7. Sensitization and sensitivity: Defining the unsensitized patient
8. Acute humoral rejection in kidney transplantation
9. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells
10. Hyperacute' renal-homograft rejection in man
11. Significance of the positive crossmatch test in kidney transplantation
12. Kidney transplantation in modified recipients
13. Transplantation in miniature swine. VII. Evidence for cellular immune mechanisms in hyperacute rejection of renal allografts
14. Humoral antibodies in renal allotransplantation in man
15. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation
16. The significance of anti-class I antibody response. Clinical and pathologic features of anti-class I mediated rejection
17. The significance of anti-class I antibody response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody
18. The renal allograft biopsy
19. Pathologic features of acute renal allograft rejection associated with donor-specific antibody
20. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries
21. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin
22. Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome
23. Acute humoral rejection in renal allograft recipients: Incidence, serology and clinical characteristics
24. Chronic rejection and chronic cyclosporine toxicity in renal allografts
25. Chronic humoral rejection: Identification of antibody mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries
26. Soluble HLA antigens, anti-HLA antibodies, and anti-idiotype antibodies in the circulation of renal transplant recipients
27. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection
28. Postoperative production of anti-donor antibody and chronic rejection in renal transplantation
29. Why do we reject a graft? Role of indirect allo-recognition in graft rejection
30. Development of cytotoxic antibodies following renal allograft transplantation is associated with reduced graft survival due to chronic vascular rejection
31. Prevalence of chronic humoral rejection in chronic renal allograft dysfunction
32. Renal transplantation after removal of anti-HLA antibodies
33. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation
34. Immunosuppressive strategies in transplantation
35. Long-term outcome after treatment of early refractory acute humoral rejection in kidney transplantation
36. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match positive recipients
37. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants
38. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins
39. Intravenous immuno-globulin suppression of HLA antibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ
40. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action
41. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody
42. Rapamycin in transplantation: A review of the evidence
43. Sirolimus-tacrolimus combination
44. Tolerance to vascularized organ allografts in large-animal models
45. Mixed chimerism as an approach for the induction of transplantation tolerance
46. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopeietic chimerism
47. The abrogation of allosensitization following the induction of mixed allogeneic chimerism